Cancer patients are surviving longer thanks to breakthrough treatments like targeted therapies. With the additional longevity, however, is the responsibility to consider other health issues that may manifest, either due to treatments such as [...]
A recent article in the Clinical Cancer Research Journal discussed a new drug, Ponatinib, that shows therapeutic potential for drug-resistant KIT mutations in GIST.
The U.S. Food and Drug Administration (FDA) has asked ARIAD Pharmaceuticals, the manufacturer of Iclusig (ponatinib) to suspend marketing and sales of ponatinib because of the risk of life-threatening blood clots and severe narrowing of [...]
ARIAD has announced that their ponatinib (Iclusig) trial, which some GIST patients are participating in, has paused new enrollment based on consultations with the FDA regarding patients who experienced particular vascular events. Subject to agreement with [...]
Here is an overview of what Jim Hughes, Pete Knox and Jerry Call learned at ASCO. There will be a more in depth article to come.